FreeTCCL Archive Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer December 01, 2014Vol.37 No.11
FreeTCCL Archive PD-1 Checkpoint Inhibitor Opdivo First to Demonstrate Survival Benefit in Phase III December 01, 2014Vol.37 No.11
Free Brigham & Women’s Suspends Controversial Morcellation Study As Apparent “Difference of Opinion” with FDA Comes to Light November 26, 2014Vol.40 No.45By Matthew Bin Han Ong
Free Urgent FDA Action Turns Power Morcellation Into Rarely Used Gynecological Procedure November 26, 2014Vol.40 No.45By Matthew Bin Han Ong
Free ASCO Proposes Principles for Debate on the Future of Medicaid Programs November 21, 2014Vol.40 No.44
Conversation with The Cancer LetterFree Demetri: Morcellation Worsens Outcomes In Patients with Undiagnosed Cancers November 21, 2014Vol.40 No.44By Matthew Bin Han Ong
Free As FDA Weighs its Options on Morcellation, Debate Erupts Over Harvard Device Study 2 November 21, 2014Vol.40 No.44
